Why do psychedelic experiences so often feel spiritual, sacred, or life-changing? Why are mystical-type experiences so closely linked to lasting therapeutic benefit? And why does medicine struggle to talk about them at all?

In this episode, we explore the neuroscience and psychology behind mystical experiences in psychedelics. We examine how shifts in brain networks involved in meaning, identity, and self-referential thinking can give rise to experiences of unity, insight, and transcendence, and why these subjective moments may matter more than the drug itself.

A grounded exploration of what psychedelic science is revealing about meaning, consciousness, and healing.

NAD has become one of the most talked-about molecules in longevity medicine—showing up in supplements, IV clinics, lab testing, and bold claims about aging and healthspan. But what does the science actually show?

In this episode of The Trip Lab, we take a clear, evidence-based look at NAD and use it as a lens to explore the broader field of longevity medicine. We break down what NAD does in the human body, why it’s linked to the hallmarks of aging, and why declining NAD is often a signal of cumulative cellular stress rather than a simple deficiency.

We also dive into the realities of NAD testing, the limitations of blood-based biomarkers, and what clinical trials of NR and NMN supplementation have—and have not—demonstrated so far. Along the way, we unpack why longevity research is both exciting and vulnerable to overhype, and why translating aging biology into meaningful human outcomes takes time.

This episode is for anyone curious about longevity medicine who wants clarity without hype—and a better framework for thinking about promise versus proof.

In this Deep Dive episode of The Trip Lab, we unpack hyperlipidemia (high cholesterol) beyond the oversimplified “LDL bad, HDL good” narrative. We also take a clear-eyed look at the most common concerns people have about statins, what the evidence actually shows, and where these medications fit—and don’t fit—within a thoughtful, individualized approach to cardiovascular risk.

From there, we explore integrative strategies for managing elevated cholesterol and why, for many patients, lifestyle, metabolic health, and inflammation-targeted interventions may be more effective than medications alone.

In this episode, we discuss:

• Why cholesterol is biologically essential and not inherently pathological
• The limitations of relying on LDL alone to assess cardiovascular risk
• How inflammation, insulin resistance, genetics, hormones, and lifestyle influence lipid metabolism
• When elevated cholesterol truly signals disease—and when it may reflect a compensatory or adaptive response
• The role of advanced markers such as ApoB, Lp(a), hsCRP and CAC scores
• Why risk stratification—not fear-based medicine—should guide clinical decision-making
• What statins can (and cannot do) and we break down the concerns people have with them
• Why integrative approaches (nutrition, exercise, herbal options and mind-body medicine) truly treat the root cause of disease

This episode is for clinicians, patients, and anyone looking to move beyond simplistic cholesterol narratives toward a more nuanced, evidence-based understanding of cardiovascular health.